We further wanted the functional validation with experimental evidence demonstrating the biological impact of the CCDC32/CBX3 fusion on AML pathogenesis or treatment resistance using patient-specific MV4–11 Cell Line (FLT3-Mutated AML) (Fig. 9). This evidence concerns the gene FLT3 and acute myeloid leukemia.